| Year |
Citation |
Score |
| 2020 |
Breen L, Gaule PB, Canonici A, Walsh N, Collins DM, Cremona M, Hennessy BT, Duffy MJ, Crown J, Donovan NO, Eustace AJ. Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A. Investigational New Drugs. PMID 32318883 DOI: 10.1007/S10637-020-00937-Y |
0.439 |
|
| 2020 |
Canonici A, Browne AL, Ibrahim MFK, Fanning KP, Roche S, Conlon NT, O'Neill F, Meiller J, Cremona M, Morgan C, Hennessy BT, Eustace AJ, Solca F, O'Donovan N, Crown J. Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer. Therapeutic Advances in Medical Oncology. 12: 1758835919897546. PMID 32064003 DOI: 10.1177/1758835919897546 |
0.311 |
|
| 2020 |
Gaynor N, Blanco A, Canonici A, Eustace AJ, McDermott M, Moran B, Fletcher JM, O'Donovan N, Crown J, Collins DM. Abstract 951: The effect of neo-adjuvant chemotherapy on immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients Immunology. DOI: 10.1158/1538-7445.Am2020-951 |
0.337 |
|
| 2019 |
Eustace A, Roche S, Mukherjee N, O’Neill F, Conlon N, Meiller J, Collins D, Gaule P, Canonici A, Madden S, O’Donovan N, Crown J. Preclinical evaluation targeting both IGF1R and IR in triple negative breast cancer Annals of Oncology. 30: v782-v783. DOI: 10.1093/Annonc/Mdz268.069 |
0.377 |
|
| 2018 |
Canonici A, Ivers L, Conlon NT, Pedersen K, Gaynor N, Browne BC, O'Brien NA, Gullo G, Collins DM, O'Donovan N, Crown J. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer. Investigational New Drugs. PMID 30062574 DOI: 10.1007/S10637-018-0649-Y |
0.423 |
|
| 2018 |
Canonici A, Qadir Z, Conlon NT, Collins DM, O'Brien NA, Walsh N, Eustace AJ, O'Donovan N, Crown J. The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells. Investigational New Drugs. PMID 29396630 DOI: 10.1007/S10637-017-0556-7 |
0.368 |
|
| 2018 |
Conlon N, Canonici A, Morgan C, Cremona M, Hennessey B, Eustace A, O'Brien N, Slamon D, Crown J, O'Donovan N. Abstract P4-03-15: Targeting Src kinase blocks development of afatinib resistance in HER2-positive breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P4-03-15 |
0.423 |
|
| 2017 |
McDermott MSJ, Canonici A, Ivers L, Browne BC, Madden SF, O'Brien NA, Crown J, O'Donovan N. Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells. International Journal of Oncology. PMID 28498399 DOI: 10.3892/Ijo.2017.3976 |
0.359 |
|
| 2016 |
Gaynor N, Canonici A, Eustace A, McDermott M, O'Donovan N, Crown J, Collins D. The effector capacity of peripheral blood mononuclear cells (PBMCs) from HER2+ breast cancer (BC) patients treated with chemotherapy and HER2-targeted therapies (ICORG 10-05) Annals of Oncology. 27: viii5. DOI: 10.1093/Annonc/Mdw525.14 |
0.33 |
|
| 2015 |
Canonici A, Conlon N, Morgan C, Cremona M, Eustace AJ, Hennessy B, Crown J, O'Donovan N. Mechanisms of acquired afatinib resistance in HER2-positive breast cancer cells. Journal of Clinical Oncology. 33: 620-620. DOI: 10.1200/Jco.2015.33.15_Suppl.620 |
0.372 |
|
| 2014 |
Ibrahim MF, Canonici A, Collins D, Crown J, O'Donovan N. Effect of afatinib alone and in combination with dasatinib in triple-negative breast cancer cell lines. Journal of Clinical Oncology. 32: 1128-1128. DOI: 10.1200/Jco.2014.32.15_Suppl.1128 |
0.392 |
|
| 2013 |
Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, O'Brien NA, Roxanis I, Li JL, Bridge E, Finn R, Siamon D, McGowan P, Duffy MJ, O'Donovan N, et al. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. 4: 1592-605. PMID 24009064 DOI: 10.18632/Oncotarget.1148 |
0.368 |
|
| 2012 |
Canonici A, Pellegrino E, Siret C, Terciolo C, Czerucka D, Bastonero S, Marvaldi J, Lombardo D, Rigot V, André F. Saccharomyces boulardii improves intestinal epithelial cell restitution by inhibiting αvβ5 integrin activation state. Plos One. 7: e45047. PMID 23028753 DOI: 10.1371/Journal.Pone.0045047 |
0.566 |
|
| 2012 |
Canonici A, Pedersen K, Browne B, McDermott M, Walsh N, Crown J, O'Donovan N. Effect of afatinib alone and in combination with trastuzumab in HER2-positive breast cancer cell lines. Journal of Clinical Oncology. 31: 632-632. DOI: 10.1200/Jco.2012.30.15_Suppl.632 |
0.381 |
|
| 2011 |
Canonici A, Siret C, Pellegrino E, Pontier-Bres R, Pouyet L, Montero MP, Colin C, Czerucka D, Rigot V, André F. Saccharomyces boulardii improves intestinal cell restitution through activation of the α2β1 integrin collagen receptor. Plos One. 6: e18427. PMID 21483797 DOI: 10.1371/Journal.Pone.0018427 |
0.567 |
|
| 2009 |
Oldani A, Cormont M, Hofman V, Chiozzi V, Oregioni O, Canonici A, Sciullo A, Sommi P, Fabbri A, Ricci V, Boquet P. Helicobacter pylori counteracts the apoptotic action of its VacA toxin by injecting the CagA protein into gastric epithelial cells. Plos Pathogens. 5: e1000603. PMID 19798427 DOI: 10.1371/Journal.Ppat.1000603 |
0.421 |
|
| 2008 |
Canonici A, Steelant W, Rigot V, Khomitch-Baud A, Boutaghou-Cherid H, Bruyneel E, Van Roy F, Garrouste F, Pommier G, André F. Insulin-like growth factor-I receptor, E-cadherin and alpha v integrin form a dynamic complex under the control of alpha-catenin. International Journal of Cancer. 122: 572-82. PMID 17955485 DOI: 10.1002/Ijc.23164 |
0.692 |
|
| 2006 |
Berruyer C, Pouyet L, Millet V, Martin FM, LeGoffic A, Canonici A, Garcia S, Bagnis C, Naquet P, Galland F. Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor gamma activity. The Journal of Experimental Medicine. 203: 2817-27. PMID 17145956 DOI: 10.1084/Jem.20061640 |
0.587 |
|
| Show low-probability matches. |